NASDAQ:OCUP Ocuphire Pharma (OCUP) Stock Price, News & Analysis → Gold Mania (From Stansberry Research) (Ad) Free OCUP Stock Alerts $1.85 +0.21 (+12.80%) (As of 05:27 PM ET) Add Compare Share Share Today's Range$1.65▼$1.9950-Day Range$1.51▼$2.6452-Week Range$1.50▼$6.60Volume663,090 shsAverage Volume216,180 shsMarket Capitalization$47.38 millionP/E RatioN/ADividend YieldN/APrice Target$19.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Ocuphire Pharma alerts: Email Address Ocuphire Pharma MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside927.0% Upside$19.00 Price TargetShort InterestBearish6.17% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingAcquiring Shares$74,100 Bought Last QuarterProj. Earnings GrowthGrowingFrom ($0.53) to ($0.42) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.44 out of 5 starsMedical Sector699th out of 908 stocksPharmaceutical Preparations Industry314th out of 419 stocks 3.5 Analyst's Opinion Consensus RatingOcuphire Pharma has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageOcuphire Pharma has only been the subject of 1 research reports in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted6.17% of the outstanding shares of Ocuphire Pharma have been sold short.Short Interest Ratio / Days to CoverOcuphire Pharma has a short interest ratio ("days to cover") of 7.1.Change versus previous monthShort interest in Ocuphire Pharma has recently increased by 0.64%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldOcuphire Pharma does not currently pay a dividend.Dividend GrowthOcuphire Pharma does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for OCUP. Previous Next 0.6 News and Social Media Coverage Search Interest18 people have searched for OCUP on MarketBeat in the last 30 days. This is an increase of 29% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added Ocuphire Pharma to their MarketBeat watchlist in the last 30 days. This is a decrease of -80% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Ocuphire Pharma insiders have bought more of their company's stock than they have sold. Specifically, they have bought $74,100.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 8.70% of the stock of Ocuphire Pharma is held by insiders.Percentage Held by InstitutionsOnly 14.97% of the stock of Ocuphire Pharma is held by institutions. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Ocuphire Pharma are expected to grow in the coming year, from ($0.53) to ($0.42) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Ocuphire Pharma is -3.85, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Ocuphire Pharma is -3.85, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioOcuphire Pharma has a P/B Ratio of 0.84. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Stansberry Research$5,000 Gold?Former Wall Street Banker Reveals Mysterious Gold Leverage As gold continues to soar, this ex-Goldman Sachs VP says DON'T buy bullion or mining stocks. Instead, he's just shared a "gold bank" that uses about $10 of your money to harness the power of two ounces of pure gold (worth about $4,200 right now).Find out how to do right here in this free video. About Ocuphire Pharma Stock (NASDAQ:OCUP)Ocuphire Pharma, Inc., a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. The company offers Phentolamine Ophthalmic Solution for reversal of mydriasis, as well as is in Phase III clinical trials for presbyopia and dim light or night vision disturbances. Its lead retinal product candidate is APX3330, a small-molecule inhibitor of reduction oxidation effector factor-1 protein that has completed Phase II clinical trial for the treatment of diabetic retinopathy. The company also develops APX2009 and APX2014 that are preclinical product candidates for retina indications. The company was founded in 2018 and is headquartered in Farmington Hills, Michigan.Read More OCUP Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart OCUP Stock News HeadlinesApril 24, 2024 | finance.yahoo.comOcuphire Pharma, Inc. (OCUP)April 22, 2024 | globenewswire.comOcuphire Pharma Announces APX3330 Presentation at ARVO 2024 Annual MeetingMay 2, 2024 | Stansberry Research (Ad)$5,000 Gold?Former Wall Street Banker Reveals Mysterious Gold Leverage As gold continues to soar, this ex-Goldman Sachs VP says DON'T buy bullion or mining stocks. Instead, he's just shared a "gold bank" that uses about $10 of your money to harness the power of two ounces of pure gold (worth about $4,200 right now).April 11, 2024 | globenewswire.comFirst Patient Enrolled in LYNX-2 Phase 3 Study Evaluating Phentolamine Ophthalmic Solution 0.75% (PS) for the Treatment of Decreased Visual Acuity Under Low Light Conditions Following Keratorefractive SurgeryApril 1, 2024 | markets.businessinsider.comOcuphire Announces Commercial Launch Of Ryzumvi In U.S. By Its Partner ViatrisApril 1, 2024 | globenewswire.comOcuphire Announces the U.S. Commercial Launch of RYZUMVl™ (Phentolamine Ophthalmic Solution 0.75%) by its Partner ViatrisMarch 27, 2024 | investing.comOcuphire Pharma COO acquires $4.1k in company stockMarch 15, 2024 | investorplace.comOCUP Stock Earnings: Ocuphire Pharma Misses EPS, Misses Revenue for Q4 2023May 2, 2024 | Stansberry Research (Ad)$5,000 Gold?Former Wall Street Banker Reveals Mysterious Gold Leverage As gold continues to soar, this ex-Goldman Sachs VP says DON'T buy bullion or mining stocks. Instead, he's just shared a "gold bank" that uses about $10 of your money to harness the power of two ounces of pure gold (worth about $4,200 right now).March 13, 2024 | finance.yahoo.comEarnings Update: Ocuphire Pharma, Inc. (NASDAQ:OCUP) Just Reported And Analysts Are Trimming Their ForecastsMarch 11, 2024 | markets.businessinsider.comBuy Rating Affirmed for Ocuphire Pharma on Promising APX3330 Progress for Diabetic Retinopathy TreatmentMarch 10, 2024 | finance.yahoo.comOcuphire Pharma Full Year 2023 Earnings: Misses ExpectationsMarch 8, 2024 | globenewswire.comOcuphire Pharma Announces Financial Results for Fourth Quarter and Full Year 2023 and Provides Corporate UpdateMarch 4, 2024 | msn.comOcuphire (OCUP) to Report Q4 Earnings: What's in the Cards?February 26, 2024 | investorplace.com7 Under-the-Radar Biotech Stocks Gearing Up for LiftoffFebruary 23, 2024 | globenewswire.comOcuphire Pharma to Present in the BIO CEO & Investor ConferenceFebruary 15, 2024 | globenewswire.comOcuphire Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)February 15, 2024 | uk.investing.comOcuphire Pharma Inc (OCUP)February 14, 2024 | finance.yahoo.comOcuphire Pharma Strengthens Leadership Team with Key AppointmentsFebruary 14, 2024 | globenewswire.comOcuphire Pharma Strengthens Leadership Team with Key AppointmentsFebruary 5, 2024 | finance.yahoo.comOcuphire Pharma Announces Presentation on APX3330 at the Annual Angiogenesis, Exudation, and Degeneration 2024 ConferenceJanuary 24, 2024 | finance.yahoo.comOcuphire Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)January 10, 2024 | msn.comOcuphire Pharma files for a $175M mixed securities shelfJanuary 4, 2024 | finance.yahoo.comOcuphire Pharma Receives FDA Agreement Under Special Protocol Assessment for LYNX-2 Phase 3 Trial of Phentolamine Ophthalmic Solution for the Treatment of Decreased Visual Acuity under Dim (mesopic) Light ConditionsNovember 30, 2023 | markets.businessinsider.comBuy Rating Affirmed for Ocuphire Pharma on Promising Clinical Advancements and Strategic PartnershipsNovember 30, 2023 | msn.comBears are Losing Control Over Ocuphire Pharma, Inc. (OCUP), Here's Why It's a 'Buy' NowNovember 27, 2023 | msn.comOcuphire announces appointment of Joseph Schachle as chief operating officerSee More Headlines Receive OCUP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Ocuphire Pharma and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/08/2024Today5/02/2024Next Earnings (Estimated)5/20/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:OCUP CUSIPN/A CIK1228627 Webwww.ocuphire.com Phone(248) 681-9815Fax240-268-5310Employees14Year FoundedN/APrice Target and Rating Average Stock Price Target$19.00 High Stock Price Target$20.00 Low Stock Price Target$17.00 Potential Upside/Downside+927.7%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($0.48) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-9,990,000.00 Net Margins-52.42% Pretax Margin-52.36% Return on Equity-22.30% Return on Assets-20.27% Debt Debt-to-Equity RatioN/A Current Ratio13.35 Quick Ratio13.35 Sales & Book Value Annual Sales$19.05 million Price / Sales2.49 Cash FlowN/A Price / Cash FlowN/A Book Value$2.20 per share Price / Book0.84Miscellaneous Outstanding Shares25,610,000Free Float22,654,000Market Cap$47.35 million OptionableOptionable Beta0.39 Investing Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free Report Key ExecutivesMr. Richard J. Rodgers M.B.A. (Age 57)Interim President & Director Comp: $62kMr. Bernhard Hoffmann M.B.A. (Age 68)Senior Vice President of Corporate Development & Operations and Secretary Comp: $348.96kMs. Amy Zaremba Rabourn C.P.A. (Age 43)MAcc, Senior Vice President of Finance Comp: $384.52kMr. George Magrath M.B.A.M.D., M.S., CEO & DirectorMr. Nirav Suresh Jhaveri C.F.A.Chief Financial OfficerMr. Joseph K. Schachle MBA (Age 59)Chief Operating Officer Dr. Ashwath Jayagopal Ph.D.Chief Scientific & Development OfficerDr. Daniela C. Oniciu Ph.D.Global Head of R&D, Chemistry and Product DevelopmentDr. Mitchell Brigell Ph.D.Head of Clinical Development & StrategyMr. Chris ErnstGlobal Head of QA & ManufacturingMore ExecutivesKey CompetitorsUnicycive TherapeuticsNASDAQ:UNCYLexaria BioscienceNASDAQ:LEXXXilio TherapeuticsNASDAQ:XLOApollomicsNASDAQ:APLMProMIS NeurosciencesNASDAQ:PMNView All CompetitorsInsiders & InstitutionsRice Hall James & Associates LLCSold 279,792 shares on 4/23/2024Ownership: 1.177%Nirav S JhaveriBought 10,000 shares on 3/21/2024Total: $21,000.00 ($2.10/share)Joseph K SchachleBought 2,000 shares on 3/21/2024Total: $4,100.00 ($2.05/share)George MagrathBought 25,000 shares on 3/18/2024Total: $49,000.00 ($1.96/share)Richmond Brothers Inc.Sold 115,234 shares on 2/8/2024Ownership: 1.117%View All Insider TransactionsView All Institutional Transactions OCUP Stock Analysis - Frequently Asked Questions Should I buy or sell Ocuphire Pharma stock right now? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ocuphire Pharma in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" OCUP shares. View OCUP analyst ratings or view top-rated stocks. What is Ocuphire Pharma's stock price target for 2024? 3 brokerages have issued 1 year price targets for Ocuphire Pharma's stock. Their OCUP share price targets range from $17.00 to $20.00. On average, they predict the company's share price to reach $19.00 in the next twelve months. This suggests a possible upside of 927.0% from the stock's current price. View analysts price targets for OCUP or view top-rated stocks among Wall Street analysts. How have OCUP shares performed in 2024? Ocuphire Pharma's stock was trading at $3.01 on January 1st, 2024. Since then, OCUP shares have decreased by 38.5% and is now trading at $1.85. View the best growth stocks for 2024 here. When is Ocuphire Pharma's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024. View our OCUP earnings forecast. How were Ocuphire Pharma's earnings last quarter? Ocuphire Pharma, Inc. (NASDAQ:OCUP) posted its earnings results on Friday, March, 8th. The company reported ($0.21) earnings per share for the quarter, missing analysts' consensus estimates of ($0.07) by $0.14. The business had revenue of $1.69 million for the quarter, compared to the consensus estimate of $3.47 million. Ocuphire Pharma had a negative net margin of 52.42% and a negative trailing twelve-month return on equity of 22.30%. Who are Ocuphire Pharma's major shareholders? Ocuphire Pharma's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Rice Hall James & Associates LLC (1.18%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include George Magrath, James S J Manuso, Jay Pepose, Joseph K Schachle, Mina Sooch and Nirav S Jhaveri. View institutional ownership trends. How do I buy shares of Ocuphire Pharma? Shares of OCUP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:OCUP) was last updated on 5/2/2024 by MarketBeat.com Staff From Our PartnersUrgent Nvidia WarningAltimetryA.I. is a Tidal Wave - Here’s What to BuyChaikin AnalyticsTruth about Trump you’ve never heardPorter & CompanyHe Is Giving Away BitcoinCrypto Swap ProfitsThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingThe A.I. story nobody is telling you (Read ASAP)TradeSmithAI “wealth window” is closing June 25thParadigm Press4 Cryptos BETTER than BitcoinTrue Market Insiders Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ocuphire Pharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
